Renal cyst growth is the main determinant for hypertension and concentrating deficit in Pkd1-deficient mice

Kidney International

Volumn 85, Issue 5, 2014, Pages 1137-1150

  Fonseca, Jonathan M ^a   Bastos, Ana P ^a   Amaral, Andressa G ^a   Sousa, Mauri F ^b   Souza, Leandro E ^a   Malheiros, Denise M ^a   Piontek, Klaus ^c   Irigoyen, Maria C ^a   Watnick, Terry J ^d   Onuchic, Luiz F ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b FEDERAL UNIVERSITY OF GOIÁS   (Brazil)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cystic kidney; Hypertension; Nitric oxide; Renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; CRE RECOMBINASE; CYSTATIN C; DIPEPTIDYL CARBOXYPEPTIDASE; RENIN; VASOPRESSIN; BIOLOGICAL MARKER; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; GENE; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HOMOZYGOSITY; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INTRON; KIDNEY POLYCYSTIC DISEASE; KIDNEY TUBULE FUNCTION; MEAN ARTERIAL PRESSURE; MORBIDITY; MORTALITY; MOUSE; NONHUMAN; OSMOLALITY; OXIDATIVE STRESS; PATHOGENESIS; PKD1 GENE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; 129 MOUSE; ANIMAL; ARTERIAL PRESSURE; BLOOD; C57BL MOUSE; COMPLICATION; DEFICIENCY; DISEASE COURSE; DISEASE MODEL; GENE EXPRESSION REGULATION; GENETICS; GENOTYPE; KIDNEY; KIDNEY CONCENTRATING CAPACITY; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; TIME; URINE;

ANIMALS; APOPTOSIS; ARTERIAL PRESSURE; BIOLOGICAL MARKERS; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; GENE EXPRESSION REGULATION; GENOTYPE; GLOMERULAR FILTRATION RATE; HYPERTENSION; KIDNEY; KIDNEY CONCENTRATING ABILITY; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; PHENOTYPE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RENIN-ANGIOTENSIN SYSTEM; TIME FACTORS; TRPP CATION CHANNELS;

EID: 84899894827     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2013.501     Document Type: Article

References (45)

1. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009; 76: 149-168.
2. Reed BY, McFann K, Bekheirnia MR et al. Variation in age at ESRD in autosomal dominant polycystic kidney disease. Am J Kidney Dis 2008; 51: 173-183.
3. Rossetti S, Consugar MB, Chapman AB et al. Comprehensive molecular diagnostics in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 2143-2160.
4. Hateboer N, van Dijk MA, Bogdanova N et al. Comparison of phenotypes of polycystic kidney disease types 1 and Lancet 1999; 353: 103-107.
5. Dicks E, Ravani P, Langman D et al. Incident renal events and risk factors in autosomal dominant polycystic kidney disease: a population and family-based cohort followed for 22 years. Clin J Am Soc Nephrol 2006; 1: 710-717.
6. Pirson Y. Extrarenal manifestations of autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: 173-180.
7. Ecder T, Schrier RW. Cardiovascular abnormalities in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2009; 5: 221-228.
8. Kelleher CL, McFann KK, Johnson AM et al. Characteristics of hypertension in young adults with autosomal dominant polycystic kidney disease compared with the general U.S. population. Am. J. Hypertens 2004; 17: 1029-1034.
9. Oflaz H, Alisir S, Buyukaydin B et al. Biventricular diastolic dysfunction in patients with autosomal-dominant polycystic kidney disease. Kidney Int 2005; 68: 2244-2249.
10. Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol 1997; 8: 1560-1567.
11. Chapman AB, Stepniakowski K, Rahbari-Oskoui F. Hypertension in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis 2010; 17: 153-163.
12. Wang D, Iversen J, Wilcox CS et al. Endothelial dysfunction and reduced nitric oxide in resistance arteries in autosomal-dominant polycystic kidney disease. Kidney Int 2003; 64: 1381-1388.
13. Martinez-Maldonado M, Yium JJ, Eknoyan G et al. Adult polycystic kidney disease: studies of the defect in urine concentration. Kidney Int 1972; 2: 107-113.
14. Fick GM, Duley IT, Johnson AM et al. The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 1994; 4: 1654-1660.
15. Torres VE. Vasopressin antagonists in polycystic kidney disease. Kidney Int 2005; 68: 2405-2418.
16. Danielsen H, Nielsen AH, Pedersen EB et al. Exaggerated natriuresis in adult polycystic kidney disease. Acta Med Scand 1986; 219: 59-66.
17. Michalski A, Grzeszczak W. The effect of hypervolemia on electrolyte level and level of volume regulating hormones in patients with autosomal dominant polycystic kidney disease. Pol Arch Med Wewn 1996; 96: 329-343.
18. Gattone VH 2nd, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003; 9: 1323-1326.
19. Torres VE, Wang X, Qian Q et al. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 2004; 10: 363-364.
20. Piontek KB, Huso DL, Grinberg A et al. A functional floxed allele of Pkd1 that can be conditionally inactivated in vivo. J Am Soc Nephrol 2004; 15: 3035-3043.
21. Shillingford JM, Piontek KB, Germino GG et al. Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1. J Am Soc Nephrol 2010; 21: 489-497.
22. Bastos AP, Piontek K, Silva AM et al. Pkd1 haploinsufficiency increases renal damage and induces microcyst formation following ischemia/ reperfusion. J Am Soc Nephrol 2009; 20: 2389-2402.
23. Kobori H, Nangaku M, Navar LG et al. The intrarenal renin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease. Pharmacol Rev 2007; 59: 251-287.
24. Boletta A, Qian F, Onuchic LF et al. Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells. Mol Cell 2000; 6: 1267-1273.
25. Nickel C, Benzing T, Sellin L et al. The polycystin-1 C-terminal fragment triggers branching morphogenesis and migration of tubular kidney epithelial cells. J Clin Invest 2002; 109: 481-489.
26. Luyten A, Su X, Gondela S et al. Aberrant regulation of planar cell polarity in polycystic kidney disease. J Am Soc Nephrol 2010; 21: 1521-1532.
27. Torres VE, Harris PC. Polycystic kidney disease in 2011: connecting the dots toward a polycystic kidney disease therapy. Nat Rev Nephrol 2011; 8: 66-68.
28. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007; 369: 1287-1301.
29. Loghman-Adham M, Soto CE, Inagami T et al. The intrarenal reninangiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 2004; 287: 775-788.
30. Torres VE, Donovan KA, Sicli G et al. Synthesis of renin by tubulocystic epithelium in autosomal dominant polycystic kidney disease. Kidney Int 1992; 42: 364-373.
31. Graham PC, Lindop GB. The anatomy of the renin-secreting cell in adult polycystic kidney disease. Kidney Int 1988; 33: 1084-1090.
32. Chapman AB, Johnson A, Gabow PA et al. The renin-angiotensinaldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096.
33. Doulton TW, Saggar-Malik AK, He FJ et al. The effect of sodium and angiotensin-converting enzyme inhibition on the classic circulating reninangiotensin system in autosomal-dominant polycystic kidney disease patients. J Hypertens 2006; 24: 939-945.
34. Valvo E, Gammaro L, Tessitore N et al. Hypertension of polycystic kidney disease: mechanisms and hemodynamic alterations. Am J Nephrol 1985; 5: 176-181.
35. Wang D, Iversen J, Strandgaard S. Endothelium-dependent relaxation of small resistance vessels is impaired in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2000; 11: 1371-1376.
36. Kocaman O, Oflaz H, Yekeler E et al. Endothelial dysfunction and increased carotid intima-media thickness in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2004; 43: 854-860.
37. Muto S, Aiba A, Saito Y et al. Pioglitazone improves the phenotype and molecular defects of a targeted Pkd1 mutant. Hum Mol Genet 2002; 11: 1731-1742.
38. Seeman T, Dusek J, Vondrák K et al. Renal concentrating capacity is linked to blood pressure in children with autosomal dominant polycystic kidney disease. Physiol Res 2004; 53: 629-634.
39. Fick GM, Duley IT, Johnson AM et al. The spectrum of autosomal dominant polycystic kidney disease in children. J Am Soc Nephrol 1994; 4: 1654-1660.
40. Cowley AW Jr, Skelton MM, Kurth TM. Effects of long-term vasopressin receptor stimulation on medullary blood flow and arterial pressure. Am J Physiol 1998; 275(5 Pt 2): R1420-R1424.
41. Nicco C, Wittner M, DiStefano A et al. Chronic exposure to vasopressin upregulates ENaC and sodium transport in the rat renal collecting duct and lung. Hypertension 2001; 38: 1143-1149.
42. Chen J, Boyle S, Zhao M et al. Differential expression of the intermediate filament protein nestin during renal development and its localization in adult podocytes. J Am Soc Nephrol 2006; 17: 1283-1291.
43. Takakura A, Contrino L, Beck AW et al. Pkd1 inactivation induced in adulthood produces focal cystic disease. J Am Soc Nephrol 2008; 19: 2351-2363.
44. Betz UA, Vosshenrich CA, Rajewsky K et al. Bypass of lethality with mosaic mice generated by Cre-loxP-mediated recombination. Curr Biol 1996; 6: 1307-1316.
45. Ceroni A, Moreira ED, Mostarda CT et al. Ace gene dosage influences the development of renovascular hypertension. Clin Exp Pharmacol Physiol 2010; 37: 490-495.